Physician profile
Sameena Rahman
NPI 1093896573
$4,356.41
in general payments reported to CMS, 2019-2025
27 companies · $309 in 2025
The $309 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $80.74 · 2020: $238 · 2021: $285 · 2022: $621 · 2023: $911 · 2024: $1,912 · 2025: $309.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,750 · Food and Beverage: $1,369 · Education: $13.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,750.00 |
| Food and Beverage | $1,368.97 |
| Education | $13.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo USA, INC. | $1,750.00 | 2024 | Xiaflex |
| Mayne Pharma Commercial LLC | $369.78 | 2022-2025 | |
| Cosette Pharmaceuticals INC. | $218.36 | 2024-2025 | Vyleesi |
| Sumitomo Pharma America, INC. | $211.35 | 2023-2025 | Myfembree |
| Agile Therapeutics, INC. | $186.25 | 2021-2024 | Twirla |
| Abbvie INC. | $178.49 | 2021-2023 | |
| Astellas Pharma US INC | $158.24 | 2023 | Veozah |
| Therapeuticsmd, INC. | $157.70 | 2020-2022 | |
| Myriad Women'S Health, INC. | $145.71 | 2023 | Myrisk |
| Avion Pharmaceuticals | $137.52 | 2020-2022 | |
| Myovant Sciences INC. | $135.70 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $75.20 | 2019-2025 | |
| Lupin INC. | $71.52 | 2020 | |
| Endo Pharmaceuticals INC. | $68.20 | 2024 | Xiaflex |
| Scynexis, INC. | $56.03 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Si-Bone, INC. | $53.48 | 2019-2021 | |
| Hologic Sales and Service, LLC | $51.75 | 2022 | |
| Evofem Biosciences, INC. | $48.84 | 2021 | |
| Abbott Laboratories | $47.84 | 2020-2022 | |
| Amag Pharmaceuticals, INC. | $46.78 | 2019-2020 | |
| Coopersurgical, INC. | $39.95 | 2023 | Paragard T 380a |
| Dysis Medical, INC. | $37.46 | 2020-2022 | |
| Millicent US INC | $31.18 | 2024 | Intrarosa |
| Medtronic, INC. | $29.20 | 2021 | |
| Bioventus LLC | $21.44 | 2020 | |
| Gynesonics, INC. | $16.04 | 2023 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Allergan, INC. | $12.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sameena Rahman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.